Foundry SING1 to target Asian clinical needs

January 11, 2017

SINGAPORE - The Foundry and Lightstone Ventures (LSV) have jointly  launched Foundry SING1, Inc. to identify and address unmet clinical needs in Asia, leveraging on Singapore’s strong and growing medtech ecosystem.

Foundry SING1 will identify, incubate and deliver innovative medical device solutions for markets in Asia. The Company's initial investor is Lightstone Singapore, L.P., a Singapore-focused fund founded in 2016 by Lightstone Ventures.
"While the medtech industry has historically attempted to develop products for Asia by adapting established therapies from Western markets, Foundry SING1 intends to develop solutions primarily focussed on clinical needs in Asia with the ultimate goal of implementing these solutions globally," said Foundry SING1 President and CEO, Karun D. Naga.
The Foundry and Lightstone Ventures have a history of collaborating to create new business models and novel device technologies. A recent example is successful incubation of FIRE1, launched in 2013 in Dublin, Ireland, in partnership with Medtronic.  www.thefoundry.com www.lightstonevc.com